Abstract.
In malaria parasites, isoprenoids are synthesised by the mevalonate independent 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. Fosmidomycin, a natural antibiotic originally developed for the treatment of bacterial infections, represents an inhibitor of DOXP reductoisomerase, an essential enzyme of this pathway. In recent clinical studies it was shown that fosmidomycin is effective in curing uncomplicated Plasmodium falciparum malaria in humans. The treatment was well tolerated and resulted in a fast parasite and fever clearance. However, the high rate of recrudescence precludes the use of fosmidomycin as a monotherapy. In drug combination studies, synergy of fosmidomycin with clindamycin was observed. Clinical studies with a fosmidomycin-clindamycin combination are currently ongoing.
Similar content being viewed by others
References
Altincicek B, Kollas AK, Sanderbrand S, Wiesner J, Hintz M, Beck E, Jomaa H (2001a) GcpE is involved in the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in Escherichia coli. J Bacteriol 183:2411–2416
Altincicek B, Kollas A, Eberl M, Wiesner J, Sanderbrand S, Hintz M, Beck E, Jomaa H (2001b) LytB, a novel gene of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis in Escherichia coli. FEBS Lett 499:37–40
Beytia ED, Porter JW (1976) Biochemistry of polyisoprenoid biosynthesis. Annu Rev Biochem 45:113–142
Chakrabarti D, Azam T, DelVecchio C, Qiu L, Park YI, Allen CM (1998) Protein prenyl transferase activities of Plasmodium falciparum. Mol Biochem Parasitol 94:175–184
Couto AS, Kimura EA, Peres VJ, Uhrig ML, Katzin AM (1999) Active isoprenoid pathway in the intra-erythrocytic stages of Plasmodium falciparum: presence of dolichols of 11 and 12 isoprene units. Biochem J 341:629–637
De Macedo CS, Uhrig ML, Kimura EA, Katzin AM (2002) Characterization of the isoprenoid chain of coenzyme Q in Plasmodium falciparum. FEMS Microbiol Lett 207:13–20
Disch A, Schwender J, Muller C, Lichtenthaler HK, Rohmer M (1998) Distribution of the mevalonate and glyceraldehyde phosphate/pyruvate pathways for isoprenoid biosynthesis in unicellular algae and the cyanobacterium Synechocystis PCC 6714. Biochem J 333:381–388
Dumas R, Biou V, Halgand F, Douce R, Duggleby RG (2001) Enzymology, structure, and dynamics of acetohydroxy acid isomeroreductase. Acc Chem Res 34:399–408
Fichera ME, Roos DS (1997) A plastid organelle as a drug target in apicomplexan parasites. Nature 390:407–409
Grellier P, Valentin A, Millerioux V, Schrevel J, Rigomier D (1994) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes. Antimicrob Agents Chemother 38:1144–12148
Hecht S, Eisenreich W, Adam P, Amslinger S, Kis K, Bacher A, Arigoni D, Rohdich F (2001) Studies on the nonmevalonate pathway to terpenes: the role of the GcpE (IspG) protein. Proc Natl Acad Sci U S A 98:14837–14842
Herz S, Wungsintaweekul J, Schuhr CA, Hecht S, Luttgen H, Sagner S, Fellermeier M, Eisenreich W, Zenk MH, Bacher A, Rohdich F (2000) Biosynthesis of terpenoids: YgbB protein converts 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate to 2C-methyl-D-erythritol 2,4-cyclodiphosphate. Proc Natl Acad Sci U S A 97:2486–2490
Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, Turbachova I, Eberl M, Zeidler J, Lichtenthaler HK, Soldati D, Beck E (1999) Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285:1573–1576
Kamiya T, Hashimoto M, Hemmi K, Takeno H (1980) Hydroxyaminohydrocarbon-phosphonic acids. Fujisawa Pharmaceutical Company, US-patent no. 4206156
Köhler S, Delwiche CF, Denny PW, Tilney LG, Webster P, Wilson RJ, Palmer JD, Roos DS (1997) A plastid of probable green algal origin in apicomplexan parasites. Science 275:1485–1489
Koppisch AT, Fox DT, Blagg BS, Poulter CD (2002) E. coli MEP synthase: steady-state kinetic analysis and substrate binding. Biochemistry 41:236–243
Kremsner PG (1990) Clindamycin in malaria treatment. J Antimicrob Chemother 25:9–14
Kuemmerle HP, Murakawa T, Soneoka K, Konishi T (1985a) Fosmidomycin: a new phosphonic acid antibiotic. Part I: phase I tolerance studies. Int J Clin Pharmacol Ther Toxicol 23:515–20
Kuemmerle HP, Murakawa T, Sakamoto H, Sato N, Konishi T, De Santis F (1985b) Fosmidomycin, a new phosphonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies. Int J Clin Pharmacol Ther Toxicol 23:521–528
Kuzuyama T, Shizimu T, Takahashi S, Seto H (1998) Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway of isoprenoidbiosynthesis. Tetrahedron Lett 39:7913–7916
Lell B, Ruangweerayut R, Wiesner J, Missinou MA, Schindler A, Baranek T, Hintz M, Hutchinson D, Jomaa H, Kremsner PG (2002) Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother (in press)
Mbaya B, Rigomier D, Edorh GG, Karst F, Schrevel J (1990) Isoprenoid metabolism in Plasmodium falciparum during the intraerythrocytic phase of malaria. Biochem Biophys Res Commun 173:849–854
Missinou MA, Borrmann S, Schindler A, Issifou S Adegnika A, Matsiegui PB, Binder R, Lell B, Kremsner PG, Wiesner J, Baranek T, Jomaa H (2002) Fosmidomycin for malaria. Lancet (in press)
Okuhara M, Kuroda Y, Goto T, Okamoto M, Terano H, Kohsaka M, Aoki H, Imanaka H (1980) Studies on new phosphonic acid antibiotics. III. Isolation and characterization of FR-31564, FR-32863 and FR-33289. J Antibiot (Tokyo) 33:24–28.
Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, Delmont J, Brouqui P (2001) Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 45:932–935
Reichenberg A, Wiesner J, Weidemeyer C, Dreiseidler E, Sanderbrand S, Altincicek B, Beck E, Schlitzer M, Jomaa H (2001) Diaryl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Bioorg Med Chem Lett 11:833–835
Reuter K, Sanderbrand S, Jomaa H, Wiesner J, Steinbrecher I, Beck E, Hintz M, Klebe G, Stubbs MT (2002) Crystal structure of 1-deoxy-D-xylulose-5-phosphate reductoisomerase, a crucial enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. J Biol Chem 277:5378–5384
Rohdich F, Eisenreich W, Wungsintaweekul J, Hecht S, Schuhr CA, Bacher A (2001) Biosynthesis of terpenoids. 2C-Methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) from Plasmodium falciparum. Eur J Biochem 268:3190–3197
Rohdich F, Hecht S, Gartner K, Adam P, Krieger C, Amslinger S, Arigoni D, Bacher A, Eisenreich W (2002) Studies on the nonmevalonate terpene biosynthetic pathway: metabolic role of IspH (LytB) protein. Proc Natl Acad Sci U S A 99:1158–1163
Rohmer M (1999) The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat Prod Rep 16:565–574
Rohmer M, Knani M, Simonin P, Sutter B, Sahm H (1993) Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. Biochem J 295:517–524
Seto H, Wtanabe H, Furihata K (1996) Simultaneous operation of the mevalonate and non-mevalonate pathways in the biosynthesis of isopentenyl diphosphate in Streptomyces aeriouvifer. Tetrahedron Lett 37:7979–7982
Skelton FS, Lunan KD, Folkers K, Schnell JV, Siddiqui WA, Geiman QM (1969) Biosynthesis of ubiquinones by malarial parasites. I. Isolation of [14C]ubiquinones from cultures of rhesus monkey blood infected with Plasmodium knowlesi. Biochemistry 8:1284–1287
Tsuchiya T, Ishibashi K, Terakawa M, Nishiyama M, Itoh N, Noguchi H (1982) Pharmacokinetics and metabolism of fosmidomycin, a new phosphonic acid, in rats and dogs. Eur J Drug Metab Pharmacokinet 7:59–64
Vial HJ, Philippot JR, Wallach DF (1984) A reevaluation of the status of cholesterol in erythrocytes infected by Plasmodium knowlesi and P. falciparum. Mol Biochem Parasitol 13:53–65
Wiesner J, Hintz M, Altincicek B, Sanderbrand S, Weidemeyer C, Beck E, Jomaa H (2000) Plasmodium falciparum: detection of the deoxyxylulose 5-phosphate reductoisomerase activity. Exp Parasitol 96:182–186
Wiesner J, Henschker D, Hutchinson DB, Beck E, Jomaa H (2002) In vitro and in vivo synergy of fosmidoymcin, a new antimalerial drug, with clindamycin. Antimicrob Agents Chemother 46:2889–2894
Wunderlich F, Fiebig S, Vial H, Kleinig H (1991) Distinct lipid compositions of parasite and host cell plasma membranes from Plasmodium chabaudi-infected erythrocytes. Mol Biochem Parasitol 44:271–277
Yajima S, Nonaka T, Kuzuyama T, Seto H, Ohsawa K (2002) Crystal structure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase complexed with cofactors: implications of a flexible loop movement upon substrate binding. J Biochem (Tokyo) 131:313–317
Zeidler J, Schwender J, Müller C, Wiesner J, Weidemeyer C, Beck E, Jomaa H, Lichtenthaler HK (1998) Inhibition of the non-mevalonate 1-deoxy-D-xylulose-5-phosphate pathway of plant isoprenoid biosynthesis by fosmidomycin. Z Naturforsch C 53:980–986.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wiesner, J., Borrmann, S. & Jomaa, H. Fosmidomycin for the treatment of malaria. Parasitol Res 90 (Suppl 2), S71–S76 (2003). https://doi.org/10.1007/s00436-002-0770-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-002-0770-9